Shape does matter: Short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 818-826

  Rees, Vanessa E ^a   Bulitta, Jürgen B ^b   Nation, Roger L ^a   Tsuji, Brian T ^b   Sörgel, Fritz ^c,d   Landersdorfer, Cornelia B ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY AT BUFFALO   (United States)

^c IBMP (Institute of Biomedical and Pharmaceutical Research)   (Germany)

^d UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Antibiotic resistance; Ciprofloxacin; P. aeruginosa; Pharmacokinetic pharmacodynamic relationships

Indexed keywords

CIPROFLOXACIN; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EXPOSURE; EFFUSION; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; DRUG EFFECTS; GENETIC SELECTION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; TIME;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; SELECTION, GENETIC; TIME FACTORS;

EID: 84928171546     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku437     Document Type: Article

References (31)

1. Spellberg B, Blaser M, Guidos RJ et al. Combating antimicrobial resistance:policy recommendations to save lives. Clin Infect Dis 2011; 52 Suppl 5: S397-428.
2. Walker B, Barret S, Polasky S et al. Looming global-scale failures and missing institutions. Science 2009; 325: 1345-6.
3. Cully M. Public health: the politics of antibiotics. Nature 2014; 509:S16-7.
4. Chastre J. Evolving problems with resistant pathogens. Clin Microbiol Infect 2008; 14 Suppl 3: 3-14.
5. Carmeli Y, TroilletN, EliopoulosGMet al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-82.
6. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22: 582-610.
7. Lomovskaya O, Warren MS, Lee A et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45: 105-16.
8. Poole K, Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Top Med Chem 2001; 1: 59-71.
9. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007; 67: 351-68.
10. Van Bambeke F, Gerbaux C, Michot JM et al. Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin. J Antimicrob Chemother 1998; 42: 761-7.
11. Drusano GL, Preston SL, Fowler C et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189: 1590-7.
12. Andes DR, CraigWA. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis 1998; 27: 47-50.
13. Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
14. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 1-2.
15. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81.
16. Haeseker M, Stolk L, Nieman F et al. The ciprofloxacin target AUC:MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. Br J Clin Pharmacol 2013; 75: 180-5.
17. Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin:a new paradigm for early clinical trials. JAMA 1998; 279: 125-9.
18. Drusano GL, Johnson DE, Rosen M et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483-90.
19. Marchbanks CR, McKiel JR, Gilbert DH et al. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob Agents Chemother 1993; 37: 1756-63.
20. Tam VH, Louie A, Deziel MR et al. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 2007; 51: 744-7.
21. Tam VH, Louie A, Deziel MR et al. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis 2005; 192: 420-8.
22. Jumbe N, Louie A, Leary R et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112: 275-85.
23. Zinner SH, Gilbert D, Greer K et al. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J Antimicrob Chemother 2013; 68: 881-7.
24. Gumbo T, Louie A, Deziel MR et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51: 3781-8.
25. Louie A, Heine HS, Kim K et al. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother 2008; 52: 2486-96.
26. Cirz RT, Chin JK, Andes DR et al. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol 2005; 3: e176.
27. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-92.
28. Dwyer DJ, Belenky PA, Yang JH et al. Antibiotics induce redox-related physiological alterations as part of their lethality. Proc Natl Acad Sci USA 2014; 111: E2100-9.
29. Hansen GT, Zhao X, Drlica K et al. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents 2006; 27: 120-4.
30. Blaser J, Stone BB, Groner MC et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054-60.
31. Stevenson MI, Scott EM, Collier PS. Effect of ciprofloxacin in an in-vitro pharmacokinetic model against Pseudomonas aeruginosa isolated during cystic fibrosis lung infection. J Antimicrob Chemother 1988; 22: 491-8.